Random Non-fasting C-peptide: Bringing Robust Assessment of Endogenous Insulin Secretion to the Clinic
Overview
Affiliations
Background: Measuring endogenous insulin secretion using C-peptide can assist diabetes management, but standard stimulation tests are impractical for clinical use. Random non-fasting C-peptide assessment would allow testing when a patient is seen in clinic.
Methods: We compared C-peptide at 90 min in the mixed meal tolerance test (sCP) with random non-fasting blood C-peptide (rCP) and random non-fasting urine C-peptide creatinine ratio (rUCPCR) in 41 participants with insulin-treated diabetes [median age 72 (interquartile range 68-78); diabetes duration 21 (14-31) years]. We assessed sensitivity and specificity for previously reported optimal mixed meal test thresholds for severe insulin deficiency (sCP < 200 pmol//l) and Type 1 diabetes/inability to withdraw insulin (< 600 pmol//l), and assessed the impact of concurrent glucose.
Results: rCP and sCP levels were similar (median 546 and 487 pmol//l, P = 0.92). rCP was highly correlated with sCP, r = 0.91, P < 0.0001, improving to r = 0.96 when excluding samples with concurrent glucose < 8 mmol//l. An rCP cut-off of 200 pmol//l gave 100% sensitivity and 93% specificity for detecting severe insulin deficiency, with area under the receiver operating characteristic curve of 0.99. rCP < 600 pmol//l gave 87% sensitivity and 83% specificity to detect sCP < 600 pmol//l. Specificity improved to 100% when excluding samples with concurrent glucose < 8 mmol//l. rUCPCR (0.52 nmol/mmol) was also well-correlated with sCP, r = 0.82, P < 0.0001. A rUCPCR cut-off of < 0.2 nmol/ mmol gave sensitivity and specificity of 83% and 93% to detect severe insulin deficiency, with area under the receiver operating characteristic curve of 0.98.
Conclusions: Random non-fasting C-peptide measures are strongly correlated with mixed meal C-peptide, and have high sensitivity and specificity for identifying clinically relevant thresholds. These tests allow assessment of C-peptide at the point patients are seen for clinical care.
Exploring the potential role of C-peptide in type 2 diabetes management.
Lin Y, McCrimmon R, Pearson E Diabet Med. 2025; 42(3):e15469.
PMID: 39797595 PMC: 11823364. DOI: 10.1111/dme.15469.
The epidemiology of type 1 diabetes mellitus in older adults.
Tomic D, Harding J, Jenkins A, Shaw J, Magliano D Nat Rev Endocrinol. 2024; 21(2):92-104.
PMID: 39448829 DOI: 10.1038/s41574-024-01046-z.
Gunaid A, Ogle G, Al-Qadasi F, Al-Radaei A, Maniam J, El-Shoubaki H BMJ Paediatr Open. 2024; 8(1).
PMID: 39097331 PMC: 11298739. DOI: 10.1136/bmjpo-2024-002680.
Diabetes Study of Children of Diverse Ethnicity and Race: Study design.
Redondo M, Harrall K, Glueck D, Tosur M, Uysal S, Muir A Diabetes Metab Res Rev. 2023; 40(3):e3744.
PMID: 37888801 PMC: 10939959. DOI: 10.1002/dmrr.3744.
Builes-Montano C, Wandurraga E, Ramirez A, Ordonez J Diabetes Ther. 2023; 14(11):1959-1976.
PMID: 37736786 PMC: 10570232. DOI: 10.1007/s13300-023-01471-9.